JP2015523969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523969A5 JP2015523969A5 JP2015514193A JP2015514193A JP2015523969A5 JP 2015523969 A5 JP2015523969 A5 JP 2015523969A5 JP 2015514193 A JP2015514193 A JP 2015514193A JP 2015514193 A JP2015514193 A JP 2015514193A JP 2015523969 A5 JP2015523969 A5 JP 2015523969A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- nanoparticle
- nanoparticles
- lipid nanoparticle
- lipid nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 claims 26
- 239000002105 nanoparticle Substances 0.000 claims 18
- 229920000642 polymer Polymers 0.000 claims 6
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 4
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- LSHROXHEILXKHM-UHFFFAOYSA-N n'-[2-[2-[2-(2-aminoethylamino)ethylamino]ethylamino]ethyl]ethane-1,2-diamine Chemical compound NCCNCCNCCNCCNCCN LSHROXHEILXKHM-UHFFFAOYSA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 229920002873 Polyethylenimine Polymers 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 229940123247 Neurotransmitter antagonist Drugs 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000000507 anthelmentic effect Effects 0.000 claims 1
- -1 anthelmintic Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000001384 anti-glaucoma Effects 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 230000002141 anti-parasite Effects 0.000 claims 1
- 230000003356 anti-rheumatic effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 229940124344 antianaemic agent Drugs 0.000 claims 1
- 239000003173 antianemic agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 229940014144 folate Drugs 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003533 narcotic effect Effects 0.000 claims 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650729P | 2012-05-23 | 2012-05-23 | |
| US61/650,729 | 2012-05-23 | ||
| US201361784892P | 2013-03-14 | 2013-03-14 | |
| US61/784,892 | 2013-03-14 | ||
| PCT/US2013/042461 WO2013177421A2 (en) | 2012-05-23 | 2013-05-23 | Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523969A JP2015523969A (ja) | 2015-08-20 |
| JP2015523969A5 true JP2015523969A5 (cg-RX-API-DMAC7.html) | 2016-03-17 |
| JP6228191B2 JP6228191B2 (ja) | 2017-11-08 |
Family
ID=48539454
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514193A Active JP6228191B2 (ja) | 2012-05-23 | 2013-05-23 | 脂質コートされたアルブミンナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 |
| JP2015514189A Expired - Fee Related JP6220389B2 (ja) | 2012-05-23 | 2013-05-23 | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 |
| JP2015514192A Pending JP2015525209A (ja) | 2012-05-23 | 2013-05-23 | 脂質ナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 |
| JP2017191221A Pending JP2018002727A (ja) | 2012-05-23 | 2017-09-29 | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514189A Expired - Fee Related JP6220389B2 (ja) | 2012-05-23 | 2013-05-23 | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 |
| JP2015514192A Pending JP2015525209A (ja) | 2012-05-23 | 2013-05-23 | 脂質ナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 |
| JP2017191221A Pending JP2018002727A (ja) | 2012-05-23 | 2017-09-29 | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10307490B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2852380A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6228191B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20150020180A (cg-RX-API-DMAC7.html) |
| CN (3) | CN105163721B (cg-RX-API-DMAC7.html) |
| AU (4) | AU2013266238B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112014029247A2 (cg-RX-API-DMAC7.html) |
| CA (3) | CA2874490C (cg-RX-API-DMAC7.html) |
| MX (3) | MX353567B (cg-RX-API-DMAC7.html) |
| WO (3) | WO2013177421A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009246876B2 (en) | 2008-05-16 | 2015-04-02 | Htyr Acquisition Llc | Antibodies and processes for preparing the same |
| ES2879225T3 (es) | 2008-08-28 | 2021-11-22 | Taiga Biotechnologies Inc | Moduladores de MYC, métodos de uso de los mismos, y métodos para identificar agentes que modulan MYC |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| MX353567B (es) | 2012-05-23 | 2018-01-18 | Univ Ohio State | Composiciones de nanoparticulas de lipidos para la entrega de oligonucleotidos antisentido. |
| ES2856179T3 (es) | 2012-07-20 | 2021-09-27 | Taiga Biotechnologies Inc | Reconstitución y autorreconstitución potenciadas del compartimento hematopoyético |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9745583B2 (en) | 2013-04-30 | 2017-08-29 | Delta-Fly Pharma, Inc. | Liposome for topical administration and application thereof |
| WO2014205000A1 (en) * | 2013-06-17 | 2014-12-24 | University Of North Carolina At Chapel Hill | Polymer coated particles and methods thereof |
| AU2014292926B2 (en) | 2013-07-25 | 2020-03-05 | Exicure Operating Company | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| WO2015154002A1 (en) * | 2014-04-04 | 2015-10-08 | Ohio State Innovation Foundation | Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same |
| WO2015175965A1 (en) | 2014-05-15 | 2015-11-19 | The Research Foundation For Suny | Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof |
| WO2015187966A1 (en) | 2014-06-04 | 2015-12-10 | Aurasense Therapeutics, Llc | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| US12264344B2 (en) | 2014-08-19 | 2025-04-01 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| JP5934848B1 (ja) * | 2014-10-30 | 2016-06-15 | Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 | 局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤 |
| WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| CA2973702A1 (en) | 2015-01-14 | 2016-07-21 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
| US20160287152A1 (en) * | 2015-03-30 | 2016-10-06 | Verily Life Sciences Llc | Functionalized Nanoparticles, Methods and In Vivo Diagnostic System |
| EP3283059B1 (en) | 2015-04-13 | 2024-01-03 | CureVac Manufacturing GmbH | Method for producing rna compositions |
| HK1253405A1 (zh) * | 2015-06-05 | 2019-06-14 | MiRagen Therapeutics, Inc. | 用於治疗皮肤t细胞淋巴瘤(ctcl)的mir-155抑制剂 |
| ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| CN105288647B (zh) * | 2015-10-10 | 2018-05-25 | 中国药科大学 | 功能化白蛋白及其纳米制剂的制备方法 |
| WO2017099823A1 (en) * | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| EP4036079B1 (en) | 2015-12-22 | 2025-11-19 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| CN107951862B (zh) * | 2016-10-17 | 2021-03-12 | 南京绿叶制药有限公司 | 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法 |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CN113307858A (zh) * | 2016-12-02 | 2021-08-27 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
| WO2018107061A1 (en) * | 2016-12-09 | 2018-06-14 | Board Of Regents, The University Of Texas System | Hybrid exosomal-polymeric (hexpo) nano-platform for delivery of rnai therapeutics |
| WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| EP3932432A1 (en) | 2016-12-14 | 2022-01-05 | Janssen Biotech, Inc. | Cd8a-binding fibronectin type iii domains |
| US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
| CN109996569B (zh) * | 2016-12-22 | 2022-05-03 | 百多力股份公司 | 用于医疗装置的药物释放涂层及其制备方法 |
| US20180179577A1 (en) * | 2016-12-22 | 2018-06-28 | Jiaming HU | Lipid-polymer Hybrid Nanoparticle Biochip and Application Thereof |
| WO2018124423A1 (ko) * | 2016-12-30 | 2018-07-05 | 주식회사 삼양바이오팜 | 플라스미드 디엔에이 전달용 고분자 나노입자 조성물 및 그의 제조방법 |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
| WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| EP3607074A4 (en) | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| CN107184552B (zh) * | 2017-06-07 | 2021-03-30 | 东华大学 | 一种半乳糖化聚乙烯亚胺修饰的载药醇质体的制备方法 |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| JP7231147B2 (ja) * | 2017-06-29 | 2023-03-01 | 国立大学法人東海国立大学機構 | Ｒｎａ導入試薬及びその利用 |
| CN111133314B (zh) * | 2017-07-18 | 2025-03-04 | 阿维塔斯有限公司 | 使用连续流动的流体系统进行跨细胞膜的有效装载的传递 |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| EP4328314A3 (en) * | 2017-08-22 | 2024-03-20 | Tessera Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| CN107982537A (zh) * | 2017-11-17 | 2018-05-04 | 厦门大学 | 针对microRNA-155的治疗性药物及其应用 |
| KR102245539B1 (ko) * | 2018-02-12 | 2021-04-29 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
| EP3789043A4 (en) * | 2018-03-29 | 2022-08-03 | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences | EXTRACTION OF "MEDICINAL SOUP" FROM PLANT SOURCE AND MANUAL PREPARATION OF "MEDICINAL PLANT" AND ASSOCIATED PRODUCTS |
| EP3784252A4 (en) * | 2018-04-18 | 2022-03-16 | Oisin Biotechnologies, Inc. | FUSOGENIC LIPID DNANOPARTICLES AND METHODS FOR THEIR PRODUCTION AND USE IN TARGET CELL SPECIFIC MANUFACTURE OF A THERAPEUTIC PROTEIN AND TREATMENT OF A TARGET CELL RELATED DISEASE, CONDITION OR DISORDER |
| CN112469281B (zh) * | 2018-05-15 | 2023-05-30 | 旗舰创业创新六公司 | 有害生物防治组合物及其用途 |
| WO2019231051A1 (ko) * | 2018-06-01 | 2019-12-05 | 서강대학교 산학협력단 | 지질을 이용한 표면 개질을 통해 세포 내 섭취 효율을 향상시킨 나노입자 복합체 및 이의 제조방법 |
| US10987428B2 (en) * | 2018-06-01 | 2021-04-27 | City Of Hope | Phosphorothioate-conjugated miRNAs and methods of using the same |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| CN108743962B (zh) * | 2018-06-19 | 2021-07-02 | 东华大学 | 一种基于荧光碳点修饰的树状大分子的双载药靶向纳米平台的制备方法 |
| EP3846857A4 (en) * | 2018-09-04 | 2022-10-12 | The Board Of Regents Of The University Of Texas System | COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS |
| JP7425066B2 (ja) * | 2018-09-04 | 2024-01-30 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 核酸を臓器特異的送達するための組成物および方法 |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| EP3906039A4 (en) * | 2019-01-04 | 2023-01-18 | Oncorus, Inc. | ENCAPSULATED RNA POLYNUCLEOTIDES AND METHODS OF USE |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| CA3137031A1 (en) | 2019-05-14 | 2020-11-19 | Yosef Refaeli | Compositions and methods for treating t cell exhaustion |
| AR120080A1 (es) | 2019-09-19 | 2022-02-02 | Modernatx Inc | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos |
| US12491255B2 (en) | 2019-10-14 | 2025-12-09 | Aro Biotherapeutics Company | EPCAM binding fibronectin type III domains |
| CN119119240A (zh) | 2019-10-14 | 2024-12-13 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| CN110638759A (zh) * | 2019-10-29 | 2020-01-03 | 珠海丽凡达生物技术有限公司 | 一种用于体外转染和体内递送mRNA的制剂 |
| KR102198736B1 (ko) | 2020-01-15 | 2021-01-05 | 이화여자대학교 산학협력단 | 생체 내 약물 전달을 위한 지질 나노입자 및 이의 용도 |
| US11801304B2 (en) * | 2020-02-19 | 2023-10-31 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof |
| KR20230051172A (ko) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | 지질 나노 입자에 사용하기 위한 양이온성 지질 |
| CA3191874A1 (en) * | 2020-08-14 | 2022-02-17 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| EP4304567A1 (en) * | 2021-03-11 | 2024-01-17 | The Trustees of the University of Pennsylvania | Targeted therapeutic lipid nanoparticles and methods of use |
| WO2022221505A2 (en) | 2021-04-14 | 2022-10-20 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
| IL307595A (en) | 2021-04-14 | 2023-12-01 | Aro Biotherapeutics Company | FN3 RNA-silencing region conjugates and their uses |
| US20240417738A1 (en) * | 2021-10-22 | 2024-12-19 | Ohio State Innovation Foundation | Immunotherapies for the treatment of cancer |
| AU2022381929B2 (en) * | 2021-11-03 | 2025-07-03 | Biond Biologics Ltd. | Intracellular delivery compositions |
| KR20240123832A (ko) | 2021-12-16 | 2024-08-14 | 아퀴타스 테라퓨틱스 인크. | 지질 나노입자 제형에 사용하기 위한 지질 |
| CN114306369B (zh) * | 2021-12-23 | 2023-12-26 | 北京悦康科创医药科技股份有限公司 | 一种硫代寡核苷酸注射液及其制备方法 |
| US20250312430A1 (en) * | 2022-03-30 | 2025-10-09 | The Johns Hopkins University | Compositions of lipid nanoparticles for plasmid dna delivery to the liver and methods for preparing the same |
| EP4577193A1 (en) * | 2022-08-25 | 2025-07-02 | Ohio State Innovation Foundation | Compositions and methods for the delivery of active agents including nucleic acids |
| WO2024050310A1 (en) * | 2022-08-29 | 2024-03-07 | Sorrento Therapeutics, Inc. | Lipid-coated nanoparticles |
| WO2024136219A1 (ko) * | 2022-12-19 | 2024-06-27 | 주식회사 포스테라헬스사이언스 | 나노 입자를 포함하는 흡입 제형 및 이의 제조 방법 |
| CN121013733A (zh) * | 2023-03-31 | 2025-11-25 | 白橡树集团公司 | Archexin的脂质体组合物 |
| WO2025034965A1 (en) * | 2023-08-09 | 2025-02-13 | Board Of Regents, The University Of Texas System | Targeted therapeutic delivery of lipid nanoparticles |
| TWI880568B (zh) * | 2024-01-04 | 2025-04-11 | 訊聯生物科技股份有限公司 | 包含生物巨分子及奈米載體之組合物、包含其的醫藥組成物及其用途 |
| WO2025171027A1 (en) * | 2024-02-05 | 2025-08-14 | University Of Rhode Island Board Of Trustees | Phlip ®-lnp for targeted intracellular delivery of nucleic acid therapeutics |
| WO2025196505A2 (en) | 2024-03-22 | 2025-09-25 | Takeda Pharmaceutical Company Limited | Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US590877A (en) * | 1897-09-28 | Danger-signal for railway-crossings | ||
| US2003203A (en) * | 1933-05-15 | 1935-05-28 | Kim Young Wo | Game |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US20020022264A1 (en) * | 1995-05-26 | 2002-02-21 | Sullivan Sean M. | Delivery vehicles comprising stable lipid/nucleic acid complexes |
| US5908777A (en) * | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
| US6248720B1 (en) * | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
| US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| CA2294579C (en) | 1997-06-23 | 2007-10-09 | Sequus Pharmaceuticals, Inc. | Liposome-entrapped polynucleotide composition and method |
| US6395253B2 (en) * | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
| ATE324888T1 (de) * | 1999-06-14 | 2006-06-15 | Cancer Rec Tech Ltd | Krebstherapie |
| HUP0202327A3 (en) * | 1999-08-27 | 2004-07-28 | Inex Pharmaceuticals Corp Burn | Compositions for stimulating cytokine secretion and inducing an immune response |
| US7060291B1 (en) * | 1999-11-24 | 2006-06-13 | Transave, Inc. | Modular targeted liposomal delivery system |
| US6821955B2 (en) * | 2000-04-07 | 2004-11-23 | Baylor College Of Medicine | Macroaggregated protein conjugates as oral genetic immunization delivery agents |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| CA2445947A1 (en) * | 2001-04-30 | 2002-11-07 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
| MXPA03010893A (es) | 2001-05-30 | 2004-10-28 | Univ Leland Stanford Junior | Sistema de suministro para acidos nucleicos. |
| JP2003088371A (ja) * | 2001-09-04 | 2003-03-25 | Mitsubishi Pharma Corp | 遺伝子導入用組成物 |
| KR100484371B1 (ko) | 2001-10-25 | 2005-04-20 | 가부시키가이샤 아텍스 | 히터선부착 시트체의 제조방법 |
| JP2005516897A (ja) * | 2001-11-07 | 2005-06-09 | イネックス ファーマシューティカルズ コーポレイション | 改善された粘膜のワクチン及びその使用方法 |
| US7678386B2 (en) | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
| KR101076146B1 (ko) * | 2002-08-16 | 2011-10-21 | 렉산 팔마큐티칼스, 인크. | 사람의 Ａｋｔ-1 유전자의 발현을 저해하는 안티센스 올리고뉴클레오타이드의 용도 |
| US20040208921A1 (en) * | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| WO2004066949A2 (en) * | 2003-01-28 | 2004-08-12 | Rexahn Corporation | Antisense oligonucleotides that inhibit expression of hif-1 |
| CN100471862C (zh) | 2003-01-31 | 2009-03-25 | 雷克珊公司 | 抑制hif-1表达的反义寡核苷酸 |
| CA2551022C (en) * | 2003-09-15 | 2013-06-04 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| KR100638041B1 (ko) | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
| JP2006111591A (ja) * | 2004-10-15 | 2006-04-27 | Anges Mg Inc | 核酸医薬を標的特異的に細胞内送達するための製剤 |
| JP2006298780A (ja) * | 2005-04-15 | 2006-11-02 | Tohoku Univ | Ｈｇｆ遺伝子と粗大凝集アルブミン−ポリエチレンイミン（ｍａａ−ｐｅｉ）との複合体 |
| US20070087045A1 (en) * | 2005-10-14 | 2007-04-19 | Industrial Technology Research Institute | Lipid carrier and method of preparing the same |
| TW200800235A (en) * | 2005-10-18 | 2008-01-01 | Otsuka Pharma Co Ltd | Carrier composition for nucleic acid transport |
| CA2628300C (en) * | 2005-11-02 | 2018-04-17 | Protiva Biotherapeutics, Inc. | Modified sirna molecules and uses thereof |
| US8067380B2 (en) | 2005-12-19 | 2011-11-29 | Industrial Technology Research Institute | Glutathione-based delivery system |
| GB2450475A (en) * | 2007-06-12 | 2008-12-31 | Univ Nottingham Trent | Antimicrobial polymer nanocomposite |
| WO2009026328A2 (en) * | 2007-08-21 | 2009-02-26 | Immune Disease Institute, Inc. | Methods of delivery of agents to leukocytes and endothelial cells |
| PL208054B1 (pl) * | 2007-09-06 | 2011-03-31 | Akademia Medyczna Im Piastow Śląskich We Wrocławiu | Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie |
| EP2217221B1 (en) * | 2007-10-17 | 2018-06-27 | Korea Advanced Institute of Science and Technology | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
| WO2009061515A1 (en) * | 2007-11-09 | 2009-05-14 | Northeastern University | Self-assembling micelle-like nanoparticles for systemic gene delivery |
| EP2222851B1 (en) * | 2007-11-20 | 2017-06-28 | Ionis Pharmaceuticals, Inc. | Modulation of cd40 expression |
| CA2710983A1 (en) | 2007-12-27 | 2009-10-01 | The Ohio State University Research Foundation | Lipid nanoparticle compositions and methods of making and using the same |
| EP2265174B1 (en) | 2008-04-04 | 2018-06-06 | The Regents of The University of California | Functionalized magnetic nanoparticles and methods of use thereof |
| US8222220B2 (en) | 2008-05-13 | 2012-07-17 | George Mason Intellectual Properties, Inc. | Nanogenomics for medicine: siRNA engineering |
| MX2010012326A (es) * | 2008-05-19 | 2010-12-01 | Univ North Carolina | Metodos y composiciones que comprenden nuevos lipidos cationicos. |
| US20090312402A1 (en) * | 2008-05-20 | 2009-12-17 | Contag Christopher H | Encapsulated nanoparticles for drug delivery |
| JP2011528910A (ja) * | 2008-07-25 | 2011-12-01 | アルニラム ファーマスーティカルズ インコーポレイテッド | センス鎖中の一般塩基またはミスマッチを使用したｓｉＲＮＡサイレンシング活性の亢進 |
| US20110280913A1 (en) | 2008-07-31 | 2011-11-17 | The Ohio State University | Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders |
| JP2012506900A (ja) * | 2008-10-28 | 2012-03-22 | ウニベルシダーデ デ サンティアゴ デ コンポステラ | アニオン性ポリマーから調製されるナノ粒子系 |
| US8722082B2 (en) * | 2008-11-10 | 2014-05-13 | Tekmira Pharmaceuticals Corporation | Lipids and compositions for the delivery of therapeutics |
| EP2210589B1 (en) | 2009-01-22 | 2015-05-06 | Ludwig-Maximilians-Universität München | Vesicular phospholipid gels comprising proteinaceous substances |
| ES2351756B1 (es) * | 2009-07-28 | 2011-10-05 | Universidad Del Pais Vasco | Nanopartículas lipídicas para terapia génica. |
| EP2504452A4 (en) * | 2009-11-23 | 2014-06-11 | Univ Ohio State Res Found | MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS |
| WO2011120053A1 (en) * | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| WO2011119553A1 (en) * | 2010-03-26 | 2011-09-29 | The Ohio State University | Materials and methods related to modulation of mismatch repair and genomic stability by mir-155 |
| WO2011133504A2 (en) * | 2010-04-20 | 2011-10-27 | University Of Florida Research Foundation, Inc. | Nanozymes, methods of making nanozymes, and methods of using nanozymes |
| WO2011133868A2 (en) * | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Conformationally restricted dinucleotide monomers and oligonucleotides |
| US20110319473A1 (en) * | 2010-06-29 | 2011-12-29 | Surmodics, Inc. | Compositions and methods for enhancement of nucleic acid delivery |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| CN102552105B (zh) * | 2011-10-17 | 2014-04-02 | 复旦大学 | 一种级联脑部靶向药物递送系统及其制备方法和用途 |
| MX353567B (es) | 2012-05-23 | 2018-01-18 | Univ Ohio State | Composiciones de nanoparticulas de lipidos para la entrega de oligonucleotidos antisentido. |
-
2013
- 2013-05-23 MX MX2014014251A patent/MX353567B/es active IP Right Grant
- 2013-05-23 EP EP13794381.7A patent/EP2852380A4/en not_active Withdrawn
- 2013-05-23 WO PCT/US2013/042461 patent/WO2013177421A2/en not_active Ceased
- 2013-05-23 US US13/900,969 patent/US10307490B2/en active Active
- 2013-05-23 BR BR112014029247A patent/BR112014029247A2/pt not_active IP Right Cessation
- 2013-05-23 CN CN201380033174.1A patent/CN105163721B/zh active Active
- 2013-05-23 EP EP13794027.6A patent/EP2852381B1/en active Active
- 2013-05-23 CA CA2874490A patent/CA2874490C/en active Active
- 2013-05-23 MX MX2014014196A patent/MX2014014196A/es unknown
- 2013-05-23 EP EP13726404.0A patent/EP2852415A1/en not_active Withdrawn
- 2013-05-23 AU AU2013266238A patent/AU2013266238B2/en active Active
- 2013-05-23 KR KR1020147032915A patent/KR20150020180A/ko not_active Ceased
- 2013-05-23 BR BR112014027834A patent/BR112014027834A2/pt not_active Application Discontinuation
- 2013-05-23 KR KR1020147036014A patent/KR102169891B1/ko active Active
- 2013-05-23 AU AU2013266236A patent/AU2013266236A1/en not_active Abandoned
- 2013-05-23 JP JP2015514193A patent/JP6228191B2/ja active Active
- 2013-05-23 CA CA2874495A patent/CA2874495A1/en not_active Abandoned
- 2013-05-23 US US14/403,313 patent/US9750819B2/en active Active
- 2013-05-23 WO PCT/US2013/042458 patent/WO2013177419A2/en not_active Ceased
- 2013-05-23 JP JP2015514189A patent/JP6220389B2/ja not_active Expired - Fee Related
- 2013-05-23 AU AU2013266232A patent/AU2013266232B2/en not_active Ceased
- 2013-05-23 JP JP2015514192A patent/JP2015525209A/ja active Pending
- 2013-05-23 KR KR1020147036015A patent/KR20150032945A/ko not_active Withdrawn
- 2013-05-23 CN CN201380026005.5A patent/CN104428005B/zh active Active
- 2013-05-23 CN CN201380033165.2A patent/CN104582691A/zh active Pending
- 2013-05-23 MX MX2018000744A patent/MX384803B/es unknown
- 2013-05-23 CA CA2871477A patent/CA2871477A1/en not_active Abandoned
- 2013-05-23 US US14/403,315 patent/US20160015824A1/en not_active Abandoned
- 2013-05-23 WO PCT/US2013/042454 patent/WO2013177415A1/en not_active Ceased
-
2017
- 2017-08-29 US US15/689,667 patent/US20180021447A1/en not_active Abandoned
- 2017-09-29 JP JP2017191221A patent/JP2018002727A/ja active Pending
- 2017-10-09 AU AU2017245294A patent/AU2017245294B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523969A5 (cg-RX-API-DMAC7.html) | ||
| Jafari et al. | Designer exosomes: a new platform for biotechnology therapeutics | |
| Ge et al. | Fluorinated α-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury | |
| Prabhu et al. | Polymeric nanoparticles for targeted treatment in oncology: current insights | |
| Yadav et al. | Advances in delivery of chemotherapeutic agents for cancer treatment | |
| Muhamad et al. | Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review | |
| Fox et al. | Synthesis and in vivo antitumor efficacy of PEGylated poly (l-lysine) dendrimer− camptothecin conjugates | |
| Vllasaliu et al. | PEGylated nanomedicines: recent progress and remaining concerns | |
| Zhao et al. | Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents | |
| JP2019524885A5 (cg-RX-API-DMAC7.html) | ||
| Pishavar et al. | Co-delivery of doxorubicin and TRAIL plasmid by modified PAMAM dendrimer in colon cancer cells, in vitro and in vivo evaluation | |
| Kibria et al. | Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery | |
| Garbuzenko et al. | Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention | |
| Sah et al. | Concepts and practices used to develop functional PLGA-based nanoparticulate systems | |
| Tian et al. | Amphiphilic polymeric micelles as the nanocarrier for peroral delivery of poorly soluble anticancer drugs | |
| Van Vlerken et al. | Poly (ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery | |
| Kushwah et al. | Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment: Kushwah et al. | |
| Yellepeddi et al. | Poly (amido amine) dendrimers in oral delivery | |
| Zou et al. | Nanocarriers with tunable surface properties to unblock bottlenecks in systemic drug and gene delivery | |
| CN102858367B (zh) | 抗原或药物递送复合物 | |
| JP2017526744A5 (cg-RX-API-DMAC7.html) | ||
| Shen et al. | Taking the vehicle out of drug delivery | |
| JP2019524802A5 (cg-RX-API-DMAC7.html) | ||
| Sun et al. | Polymers in the co-delivery of siRNA and anticancer drugs for the treatment of drug-resistant cancers | |
| JP2015519346A5 (cg-RX-API-DMAC7.html) |